OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Chen on FLASH Trial Results in CTCL

October 21st 2022

Pei-Ling Chen, MD, PhD, gives her perspective on results from the phase 3 FLASH trial investigating synthetic hypericin in CTCL.

Dr. Chen Explores Possible Genomic Basis for Racial Disparities in CTCL Outcomes

October 21st 2022

Pei-Ling Chen, MD, PhD, discusses genomic findings that may explain poorer outcomes for Black patients with CTCL.

Dr. Chen on Identifying Malignant T-Cell Signatures in CTCL

October 21st 2022

Pei-Ling Chen, MD, PhD, discusses findings from a study the multiomics of patients with transformed CTCL that she led at Moffitt Cancer Center.

Dr. Chen Discusses Management of Early Stage, Advanced CTCL

October 21st 2022

Pei-Ling Chen, MD, PhD, says management of cutaneous T-cell lymphoma requires a multidisciplinary team of specialists including dermatologists and radiation oncologists.

Dr. Chen Discusses Racial Disparities in CTCL

October 21st 2022

Pei-Ling Chen, MD, PhD, discusses epidemiology and racial disparities in CTCL.

Dr. Chen Highlights Incidence of CTCL

October 21st 2022

Pei-Ling Chen, MD, PhD, discusses the incidence of CTCL.

Dr. Giaconne on the Lack of Funding for Rare Cancers Research

October 21st 2022

Giuseppe Giaccone, MD, PhD, highlights the difficulties with funding for research focused on rare cancers.

Dr. He Discusses Discovery of Cancer-Inducing Mutation in Thymic Epithelial Cells

October 21st 2022

Yongfeng He, PhD, discusses the identification of the GTF2I L424H mutation in mouse models of thymic cancer.

Dr. He Discusses Potential Therapeutic Uses for GTF2I L424+ Thymic Cancers

October 21st 2022

Yongfeng He, PhD, discusses how the presence of the GTF2I L424H mutation in thymic epithelial cells induced thymic tumors in mouse models.

Dr. Cass on Managing Diarrhea in Patients Treated With EGFR TKIs

October 21st 2022

Amanda Cass, PharmD, BCPS, BCOP, discusses strategies to manage the diarrhea that may occur as an adverse effect in patients treated with EGFR TKIs.

Emily Skotte, MSN on Rash Management in Patients Treated With EGFR TKIs

October 21st 2022

Emily Skotte, MSN, discusses common ways to manage the rashes that may occur as adverse effects in patients treated with EGFR TKIs.

Dr. Giaccone on Investigational Agents in Thymic Cancers

October 21st 2022

Giuseppe Giaccone, MD, PhD, discusses recent data with investigational therapies for patients with thymic cancer.

Dr. Giaccone on the Challenge of Diagnosing Thymic Cancers

October 21st 2022

Giuseppe Giaconne, MD, PhD, discusses why thymic cancers can be difficult to classify histologically, so the actual incidence is unclear.

Drs Giaccone and He on Raising Awareness in Thymic Cancers

October 21st 2022

Giuseppe Giaconne, MD, PhD, and Yongfeng He, PhD, discuss how cancers of the thymus, a small organ located in the mediastinum above the heart, are uncommon and understudied.

Dr. Llanos on the Role of Social and Biological Determinants on Cancer Risk

October 20th 2022

Adana A.M. Llanos, PhD, MPH, discusses the role of social and biological determinants on cancer risk.

Dr. Vunjak-Novakovic on the Clinical Need for Personalizing Cancer Care

October 20th 2022

Gordana Vunjak-Novakovic, PhD, BS, MS, discusses the clinical need for personalizing cancer care.

Dr. Baccarelli on the Effect of Environmental Factors on Cancer Diagnoses

October 20th 2022

Andrea Baccarelli, MD, PhD, discusses the effect of environmental factors on cancer diagnoses.

Dr. Camidge on Toxicities of Sunvozertinib in EGFR Exon 20–Mutated NSCLC

October 20th 2022

Ross Camidge, MD, PhD, discusses toxicities observed with sunvozertinib in EGFR exon 20–mutated non–small cell lung cancer.

Dr. Gross on the Investigation of Cemiplimab in Cutaneous Squamous Cell Carcinoma

October 20th 2022

Neil D. Gross, MD, FACS, discusses the investigation of cemiplimab in cutaneous squamous cell carcinoma.

Dr. Aggarwal on ADT Intensification in Biochemically Relapsed Prostate Cancer

October 20th 2022

Rahul Aggarwal, MD, discusses the rationale for investigating androgen deprivation therapy intensification in biochemically relapsed prostate cancer.